ALIVUS
Alivus Life Sciences Limited (ALIVUS) Stock Analysis
Alivus Life Sciences Limited is an Indian pharmaceutical company focused on APIs and complex formulations. It develops and manufactures active ingredients and finished dosages for global markets. The company was formerly part of Glenmark's API business before listing separately. It is a listed mid-cap pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,348.00
-1.62% 1W | +44.00% 52W
Market Cap
16.5k CR
P/E Ratio
27.5
52W High
₹1493.8
52W Low
₹819
Div. Yield
0.37%
Beta
0.1
50 DMA
₹1373.1
200 DMA
₹1104.6
Profit Margin
23.3%
Inst. Own.
7.3%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
No profit & loss data available.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|
| Sales | 886 | 1,537 | 1,885 |
| Expenses | 639 | 1,065 | 1,294 |
| Operating Profit | 248 | 472 | 591 |
| OPM % | 28% | 31% | 31% |
| Other Income | 0 | 12 | 1 |
| Interest | 1 | 34 | 88 |
| Depreciation | 19 | 29 | 33 |
| Profit before tax | 228 | 421 | 471 |
| Tax % | 14% | 26% | 25% |
| Net Profit | 196 | 313 | 352 |
| EPS in Rs | 997.86 | 1,597.37 | 358.74 |
| Dividend Payout % | -0% | -0% | -0% |
Shareholding Pattern
Promoters74.94%
FIIs6.42%
DIIs5.62%
Public13.03%
Promoters74.91%
FIIs6.84%
DIIs5.47%
Public12.79%
Promoters74.91%
FIIs5.08%
DIIs7.13%
Public12.89%
Promoters74.87%
FIIs5.30%
DIIs7.27%
Public12.55%
Promoters74.87%
FIIs5.54%
DIIs7.18%
Public12.42%
Promoters82.85%
FIIs3.28%
Public13.86%
Promoters82.85%
FIIs5.01%
DIIs1.41%
Public10.73%
Promoters74.99%
FIIs6.57%
DIIs5.19%
Public13.25%
Promoters74.87%
FIIs5.30%
DIIs7.27%
Public12.55%
Promoters74.87%
FIIs5.54%
DIIs7.18%
Public12.42%
ALIVUS
Holdings Analysis
Key strengths & risk signals
72
Overall
67
Fundamental
78
Technical
Risks (3)
OVERVALUED! PEG of 4.28 means expensive relative to growth rate.
RECOVERY MODE! Current price (1344.4) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -2.9% (1 week), -3.1% (1 month), 15.1% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1370.4) is above 200-day average (1102.4) - positive signal.
GOOD YEAR! Stock gained 43.3% in the last year.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 252,884 vs down days: 126,361. Ratio: 2.0x
Fundamental & Technical Analysis
70Overall
67Fundamental
73Technical
Fundamental Breakdown
Growth Quality
16/30
Revenue CAGR: 6.9% (MODERATE, 8/15). Profit CAGR: 6.5% (MODERATE, 8/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 23.3% profit margin - company keeps strong profits.
PEG Valuation
0/10
OVERVALUED! PEG of 4.23 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.37% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.02 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 13.3% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1373.1) is above 200-day average (1104.6) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1348.0) above 200-day but below 50-day.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
GOOD YEAR! Stock gained 44.0% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 165,224 vs down days: 126,361. Ratio: 1.31x
RSI
3/5
NEUTRAL! RSI at 47.8 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 78.4% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -1.6% (1 week), -2.8% (1 month), 15.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
ALIVUS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-07 | Concall PDF | |
| Q4FY262026-05-21 | Concall PDF | |
| Q2FY262026-01-30 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
| NATCOPHARM | ₹782.60 | 12.4 | 32.8% | 14.5% | 25.6% | -3.8% | 66 | BREAKDOWN | -57.0% | -22.9% | -44.7% | -0.5% |
Data from TradeAlone · Updated daily
ALIVUS News
Alivus Life Sciences Limited (alivus) Announces Acquisition of Majority Stake in Iqgenx2026-08-18Alivus Life Sciences Limited (ALIVUS) breaks out, gains 10% intraday2026-08-04Alivus Life Sciences Limited (ALIVUS) breaks out, gains 7% intraday2026-08-04Alivus Life Sciences Limited (ALIVUS) gains 5% intraday, recovers despite weak structure2026-07-31Alivus Life Sciences Limited (alivus) Q1 FY27: PAT Up 32%, Margins at 25%2026-07-30
